Assessment of biological, psychological and adherence factors in the prediction of step-down treatment for patients with well-controlled asthma

被引:11
作者
Saito, N. [1 ,2 ]
Kamata, A. [3 ]
Itoga, M. [1 ]
Tamaki, M. [4 ]
Kayaba, H. [1 ]
Ritz, T. [2 ]
机构
[1] Hirosaki Univ, Grad Sch Med, Dept Clin Lab Med, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan
[2] Southern Methodist Univ, Dept Psychol, Dallas, TX 75275 USA
[3] Southern Methodist Univ, Dept Educ Policy & Leadership, Dallas, TX 75275 USA
[4] Yokote Municipal Hosp, Dept Allergy & Resp Med, Yokote, Japan
关键词
adherence; asthma; inhaled corticosteroids; psychosocial factors; step-down treatment; upper airway comorbidity; ALLERGIC RHINITIS; INHALED CORTICOSTEROIDS; DEPRESSION SCALE; FOLLOW-UP; RHINOSINUSITIS; IMPACT; COMORBIDITY; BUDESONIDE; PREVALENCE; GUIDELINE;
D O I
10.1111/cea.12888
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background and Objective Inhaled corticosteroids (ICS) and inhaled corticosteroids combined with long-acting beta2-agonist (ICS/LABA) are standard treatments for asthma. However, factors that might help reduce medication in well-controlled asthma are unknown. We classified problems of asthma patients into biological, psychological and adherence factors, and investigated factors associated with the indication and failure of a medication step-down treatment. Methods Two hundred twenty two well-controlled asthma patients receiving ICS or ICS/LABA were assessed for physical and psychiatric problems and followed up for one year from adjustment of their treatment step. Factor B was defined as a presence of chronic upper airway complications. Factor P was defined as presence of psychiatric complications such as sleep disorder, depression, anxiety and somatoform disorders. Factor A was defined as poor adherence to ICS or ICS/LABA inhaler of 75% or less. Success in step-down treatment was defined as maintenance of well-controlled status for over one year after step-down. Results Factor B was the most important single negative predictive factor for indication for step-down treatment (Odds ratio; 0.19). Factor A increased the risk of failure to maintain step-down treatment most significantly by 23-fold, and factor B increased it by 11-fold. The combination of factors B and A increased failure by 24-fold, factors P and A by 21-fold, all three factors by 36-fold. Factor P only interacted with the other factors to reduce chances of stepping down, but did not constitute a problem factor when present alone. Conclusion and Clinical Relevance The evaluation of biological, psychological and adherence problems may lead to a more proactive and targeted approach to step-down treatment for patients with well-controlled asthma.
引用
收藏
页码:467 / 478
页数:12
相关论文
共 50 条
[1]  
[Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
[2]   The Heterogeneity Hidden in Allergic Rhinitis and Its Impact on Co-Existing Asthma in Adults: A Population-Based Survey [J].
Antonicelli, Leonardo ;
Marchetti, Pierpaolo ;
Accordini, Simone ;
Bono, Roberto ;
Carosso, Aurelia ;
Casali, Lucio ;
Cazzoletti, Lucia ;
Corsico, Angelo ;
Ferrari, Marcello ;
Fois, Alessandro ;
Nicolini, Gabriele ;
Olivieri, Mario ;
Pirina, Pietro ;
Verlato, Giuseppe ;
Villani, Simona ;
de Marco, Roberto .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2015, 168 (03) :205-212
[3]   Allergic rhinitis, rhinosinusitis, and asthma: one airway disease [J].
Bachert, C ;
Vignola, AM ;
Gevaert, P ;
Leynaert, B ;
Van Cauwenberge, P ;
Bousquet, J .
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2004, 24 (01) :19-+
[4]   Efficacy of inhaled corticosteroids in asthma [J].
Barnes, PJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) :531-538
[5]   Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma [J].
Bateman, E. D. ;
Linnhof, A. E. ;
Homik, L. ;
Freudensprung, U. ;
Smau, L. ;
Engelstaetter, R. .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2008, 21 (02) :264-275
[6]   Medication non-adherence and asthma treatment cost [J].
Bender, Bruce G. ;
Rand, Cynthia .
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 4 (03) :191-195
[7]  
Boulet LP, 2011, EXPERT REV RESP MED, V5, P377, DOI [10.1586/ers.11.34, 10.1586/ERS.11.34]
[8]   Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial [J].
Bousquet, J ;
Gaugris, S ;
Kocevar, VS ;
Zhang, Q ;
Yin, DD ;
Polos, PG ;
Bjermer, L .
CLINICAL AND EXPERIMENTAL ALLERGY, 2005, 35 (06) :723-727
[9]   Allergic rhinitis and its impact on asthma [J].
Bousquet, J ;
van Cauwenberge, P ;
Khaltaev, N ;
Ait-Khaled, N ;
Annesi-Maesano, I ;
Bachert, C ;
Baena-Cagnani, C ;
Bateman, E ;
Bonini, S ;
Canonica, GW ;
Carlsen, KH ;
Demoly, P ;
Durham, SR ;
Enarson, D ;
Fokkens, WJ ;
van Wijk, RG ;
Howarth, P ;
Ivanova, NA ;
Kemp, JP ;
Klossek, JM ;
Lockey, RF ;
Lund, V ;
Mackay, I ;
Malling, HJ ;
Meltzer, EO ;
Mygind, N ;
Okunda, M ;
Pawankar, R ;
Price, D ;
Scadding, GK ;
Simons, FER ;
Szczeklik, A ;
Valovirta, E ;
Vignola, AM ;
Wang, DY ;
Warner, JO ;
Weiss, KB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (05) :S147-S334
[10]   Rhinosinusitis in severe asthma [J].
Bresciani, M ;
Paradis, L ;
Des Roches, A ;
Vernhet, H ;
Vachier, I ;
Godard, P ;
Bousquet, J ;
Chanez, P .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (01) :73-80